Posts by Noopur S. Raje, MD
-
CAR T-cell Therapy Shows Promise for Refractory/Relapsed Multiple Myeloma
Noopur Raje, MD, and colleagues determined in a phase 1 trial that idecabtagene vicleucel had promising antitumor activity in a heavily pretreated population of patients with multiple myeloma, and most nonhematologic toxic effects were grade 1 or 2.
Biography
Dr. Raje is associate professor of medicine at Harvard Medical School and director of the Multiple Myeloma Center at Massachusetts General Hospital. She spearheads a translational research program evaluating novel therapeutics in myeloma with a special interest in the biology of myeloma bone disease. Dr. Raje is a member of the International Myeloma Working Group and NCCN Clinical Practice Guidelines Committee for Multiple Myeloma.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.